看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 11.7x - 12.9x | 12.3x |
| Selected Fwd EBIT Multiple | 10.6x - 11.7x | 11.2x |
| Fair Value | $57.23 - $65.33 | $61.28 |
| Upside | -28.3% - -18.1% | -23.2% |
| Benchmarks | Ticker | Full Ticker |
| Assertio Holdings, Inc. | ASRT | NasdaqCM:ASRT |
| ANI Pharmaceuticals, Inc. | ANIP | NasdaqGM:ANIP |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| Supernus Pharmaceuticals, Inc. | SUPN | NasdaqGM:SUPN |
| Coherus BioSciences, Inc. | CHRS | NasdaqGM:CHRS |
| Prestige Consumer Healthcare Inc. | PBH | NYSE:PBH |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| ASRT | ANIP | AMPH | SUPN | CHRS | PBH | ||
| NasdaqCM:ASRT | NasdaqGM:ANIP | NasdaqGS:AMPH | NasdaqGM:SUPN | NasdaqGM:CHRS | NYSE:PBH | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | -2.3% | NM- | -16.2% | NM- | 3.0% | |
| 3Y CAGR | NM- | NM- | 42.0% | -8.3% | NM- | 4.5% | |
| Latest Twelve Months | -182.9% | -70.5% | 2.9% | 357.8% | 51.2% | -5.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 4.9% | -1.2% | 18.1% | 15.5% | -49.3% | 30.7% | |
| Prior Fiscal Year | 16.4% | 10.2% | 31.0% | 2.2% | -75.1% | 30.8% | |
| Latest Fiscal Year | -16.6% | 2.4% | 28.1% | 9.3% | -35.3% | 30.4% | |
| Latest Twelve Months | -16.6% | 2.4% | 28.1% | 9.3% | -35.3% | 29.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | -0.02x | 3.08x | 2.12x | 1.97x | 1.13x | 4.41x | |
| EV / LTM EBITDA | -0.4x | 23.0x | 6.0x | 9.2x | -3.4x | 13.6x | |
| EV / LTM EBIT | 0.1x | 129.5x | 7.6x | 21.2x | -3.2x | 14.9x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -3.2x | 7.6x | 129.5x | ||||
| Historical EV / LTM EBIT | 11.9x | 13.0x | 13.6x | ||||
| Selected EV / LTM EBIT | 11.7x | 12.3x | 12.9x | ||||
| (x) LTM EBIT | 331 | 331 | 331 | ||||
| (=) Implied Enterprise Value | 3,867 | 4,071 | 4,274 | ||||
| (-) Non-shareholder Claims * | (976) | (976) | (976) | ||||
| (=) Equity Value | 2,891 | 3,094 | 3,298 | ||||
| (/) Shares Outstanding | 49.5 | 49.5 | 49.5 | ||||
| Implied Value Range | 58.36 | 62.46 | 66.57 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 58.36 | 62.46 | 66.57 | 79.77 | |||
| Upside / (Downside) | -26.8% | -21.7% | -16.5% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | ASRT | ANIP | AMPH | SUPN | CHRS | PBH | |
| Enterprise Value | (2) | 1,888 | 1,541 | 1,302 | 301 | 4,928 | |
| (+) Cash & Short Term Investments | 100 | 151 | 222 | 454 | 126 | 51 | |
| (+) Investments & Other | 0 | 5 | 11 | 0 | 0 | 0 | |
| (-) Debt | (40) | (631) | (651) | (34) | (299) | (1,027) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | (25) | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 58 | 1,388 | 1,123 | 1,721 | 129 | 3,952 | |
| (/) Shares Outstanding | 95.8 | 20.3 | 47.7 | 55.8 | 115.9 | 49.5 | |
| Implied Stock Price | 0.60 | 68.37 | 23.56 | 30.84 | 1.11 | 79.77 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.60 | 68.37 | 23.56 | 30.84 | 1.11 | 79.77 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |